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KEY POINTS 
 
• WT1 mRNA-electroporated dendritic cells can prevent or delay relapse in 43% of AML 
patients in remission after chemotherapy.  
• OS compares favorably with the new survival data from the SALR, and correlates with 
molecular and WT1-specific CD8+ T-cell responses. 
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ABSTRACT 
 
Relapse is a major problem in acute myeloid leukemia (AML) and adversely impacts survival. 
In this phase II study, we investigated the effect of vaccination with dendritic cells (DCs) 
electroporated with Wilms’ tumor 1 (WT1) mRNA as post-remission treatment in 30 AML 
patients at very high risk of relapse. There was a demonstrable anti-leukemic response in 13 
patients. Nine patients achieved molecular remission as demonstrated by normalization 
of WT1 transcript levels, 5 of which are sustained after a median follow-up of 109.4 months. 
Disease stabilization was achieved in 4 other patients. Five-year overall survival (OS) was 
higher in responders than in non-responders (53.8% vs. 25.0%; P=0.01). In patients 
receiving DCs in first complete remission (CR1), there was a vaccine-induced relapse 
reduction rate of 25% and the 5-year relapse-free survival was higher in responders than in 
non-responders (50% vs. 7.7%; P<0.0001). In patients ≤65 and >65 years who received DCs 
in CR1, 5-year OS was 69.2% and 30.8% respectively, as compared to 51.7% and 18% in 
the Swedish Acute Leukemia Registry (SALR). Long-term clinical response was correlated 
with increased circulating frequencies of poly-epitope WT1-specific CD8+ T-cells. Long-term 
OS was correlated with interferon-γ+ and tumor necrosis factor-α+ WT1-specific responses in 
delayed type hypersensitivity-infiltrating CD8+ T-lymphocytes. In conclusion, vaccination of 
AML patients with WT1 mRNA-electroporated DCs can be an effective strategy to prevent or 
delay relapse after standard chemotherapy, translating into improved OS rates, which are 
correlated with the induction of WT1-specific CD8+ T-cell response. This trial was registered 
at www.clinicaltrials.gov as #NCT00965224. 
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INTRODUCTION 
 
Acute myeloid leukemia (AML) still has a dismal prognosis.1,2 According to the latest data of 
the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer 
Institute,1 the 5-year overall survival (OS) of AML is only around 25%. One of the major 
reasons for this is that the majority of patients relapse even after complete remission (CR) is 
achieved with standard chemotherapy.3 Relapse is usually caused by the persistence of a 
small population of residual leukemic cells, a condition designated as minimal residual 
disease (MRD).4 Allogeneic hematopoietic stem cell transplantation (allo-HSCT), the best 
established post-remission treatment to eradicate MRD, decrease the risk of relapse and 
increase survival following chemotherapy, is still beset by substantial morbidity and 
mortality.5 As a consequence, allo-HSCT is generally not considered as a therapeutic option 
in the large group of older AML patients. For these patients and for younger patients without 
a compatible donor, there is currently no standard adjuvant treatment to prevent post-
chemotherapy relapse.4   
The beneficial effect of allo-HSCT against leukemia is mediated in large part by T-
cells that are capable of recognizing antigens expressed on the leukemia cells and of 
subsequently mediating AML cell killing.6 Stimulation of autologous T-cells by in vivo 
immunization with leukemia-associated antigens is an innovative strategy to combat relapse 
in AML,7-11 acting via the reduction or eradication of MRD. Several antigens have been 
identified to serve as T-cell targets in AML, including the Wilms’ tumor protein 1 (WT1) which 
is highly overexpressed in AML and is also involved in leukemogenesis.12 In view of their role 
as the most potent antigen-presenting cells of the immune system, dendritic cells (DCs) are 
eminently equipped to stimulate antigen-specific T-cell immunity.13 This explains the strong 
interest in the use of these cells for cancer vaccination strategies.14  
The aim of this phase II study was to determine the clinical efficacy of DC vaccine 
therapy in AML, and, more specifically, whether this form of immunotherapy can be applied 
in the adjuvant setting to decrease the risk of relapse following chemotherapy and to improve 
survival. To this end, we here vaccinated 30 AML patients in remission but at very high risk 
of relapse with autologous DCs loaded with the WT1 antigen by means of mRNA 
electroporation, a technique that allows for human leukocyte antigen (HLA) haplotype-
independent, multi-epitope antigen presentation to T-cells.15,16  
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METHODS 
 
Patients 
Thirty AML patients were enrolled in this phase II study (ClinicalTrials.gov identifier 
NCT00965224), whereby the first 10 patients were also included in a preceding feasibility, 
safety and immunogenicity study (ClinicalTrials.gov identifier NCT00834002).17 This study 
was approved by the ethics committee of the Antwerp University Hospital (UZA), Edegem, 
Antwerp, Belgium. Enrollment criteria for the phase II study were adult patients with AML 
(except acute promyelocytic leukemia), diagnosed according to World Health Organization 
(WHO) criteria, in remission after at least one course of polychemotherapy and at high risk of 
relapse as defined by: (i) age >60 years (yr) or if younger than 60 yr without matched sibling 
donor for allo-HSCT; (ii) poor risk cytogenetic or molecular markers; (iii) hyperleukocytosis at 
presentation; and/or (iv) previous relapse. 
 
DC vaccination 
Clinical grade WT1 mRNA-electroporated DC (WT1/DC) vaccines were prepared and 
administered intradermally as described previously.16,17 Three different WT1 constructs were 
used to generate mRNA by in vitro transcription (Figure 1, Table S1): construct 1 (“WT1”), 
encoding full-length WT1;16,17 construct 2 (“WT1-DC-LAMP”), incorporating a Sig-DC-LAMP 
major histocompatibility complex (MHC) class II-skewing signal with deletion of the WT1 
nuclear localization signal (NLS); and construct 3 (“WT1-DC-LAMP-OPT”), a codon-
optimized version of construct 2.18  
 
Molecular tumor marker monitoring and clinical response criteria 
Longitudinal monitoring of WT1 transcripts was performed as described previously using an 
in-house assay,17,19 the ipsogen WT1 ProfileQuant Kit (Qiagen)20 or the WT1 mRNA 
OneStep Assay (Otsuka Pharmaceutical Co).19 WT1 mRNA levels above background 
(respectively above 1 and 25 copies of WT1 mRNA per 1,000 ABL copies in blood and 
marrow in the in-house assay; according to manufacturer’s instructions in the commercial 
kits) are indicative of MRD and herald full relapse.21-25 Responders were characterized by 
molecular remission (MR) or by stable disease (SD). MR was defined by normalization of 
WT1 mRNA levels in blood and/or bone marrow during WT1/DC vaccination, while reaching 
or maintaining hematological CR. SD was defined by stable WT1 blood transcript levels 
above background, with stable blood values without blasts. The minimum duration of SD was 
2 months, after which WT1 mRNA levels did not increase by more than a factor of 0.5 log10 
and at least 1 basic blood value (hemoglobin, thrombocyte count and/or absolute neutrophil 
count) was normal. Patients who relapsed without achieving MR or SD status were 
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categorized as non-responders. The classical definitions of CR, partial remission (PR), 
relapse and survival were used.26 Long-term survivors were defined as surviving for at least 3 
yr26,27 and long-term responders as patients with a MR or SD response remaining in CR for at 
least 3 yr, after the first dose of WT1/DCs. 
 
Immunomonitoring 
Detection and subtyping of anti-WT1 antibodies in pre- and post-vaccination plasma samples 
was performed as described previously.17,28 The increase in WT1 IgG antibody levels after 
vaccination was determined by subtraction of the corresponding pre-vaccination values. 
Cytokine plasma levels were determined using the Th1/Th2 multiplex immunoassay 
(Bender MedSystems). Ex vivo flow cytometric analysis of lymphocyte subsets was 
performed using directly conjugated monoclonal antibodies (BD Biosciences).   
Circulating WT1-specific CD8+ T-cells obtained before vaccination and after the fourth 
dose of WT1/DCs were stained with peptide-HLA-A*0201 tetramers and quantified as 
described previously.17,29 Whenever cells were available they were also analyzed at different 
time points afterwards until relapse and/or progression. 
Two weeks after the 4th WT1/DC vaccination, delayed-type hypersensitivity (DTH)  
was tested against the complete vaccine (i.e. keyhole limpet hemocyanin [KLH]-exposed 
WT1/DCs, except in patients UPN11, 12, 13 where non-KLH-exposed WT1/DCs were used). 
This was performed by intradermal injection of 0.5 x 106 WT1/DCs on the back of the patient. 
Forty-eight hours later, erythema and induration at the injection site were measured and skin 
punch biopsies were taken for culture of DTH-infiltrating lymphocytes (DILs). These DILs 
were allowed to expand for 2-3 weeks in medium with interleukin (IL)-2 (100 IU/mL). 
Expanded DILs were then harvested and tested for antigen specificity as described 
previously.17 
 
Data mining and statistical analysis 
Statistical calculations and data graphing were carried out using Prism version 5.01 
(GraphPad). A P value <0.05 was considered statistically significant. 
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RESULTS 
 
Patients 
WT1/DC vaccination as a post-remission treatment was evaluated in 30 high-risk AML 
patients in remission following chemotherapy. Patient characteristics with baseline evaluation 
and initial treatments are shown in Table S1. There were 15 males and 15 females, with a 
median age at diagnosis of 65 yr. Prior to WT1/DC vaccination, 27 patients had achieved CR 
following chemotherapy, whereas 3 had partial remission (PR). Six patients had a preceding 
hematological disorder, myelodysplastic syndrome (n=5) or myeloproliferative neoplasia 
(n=1). The cytogenetic risk group30 was adverse in 1, intermediate in 23 and favorable in 6 
patients. All patients were at increased risk of relapse, as indicated by the unfavorable 
prognostic features in Table S1. In particular, WT1 transcript levels above background post-
induction and/or post-consolidation chemotherapy were predictive of relapse21-25 in 5/6, 18/23 
and 1/1 of patients with respectively favorable, intermediate and adverse cytogenetic risk. Of 
the remaining 6 patients without increased WT1 transcript levels after chemotherapy, only 1 
with erythroleukemia in the intermediate risk group (UPN22) did not relapse and his 
response was categorized as undefinable (Figure 1). 
 
Clinical response  
There was a demonstrable anti-leukemic effect of the WT1/DC vaccination only without any 
concomitant chemotherapy in 13/30 patients, corresponding to a clinical response rate of 
43%. Of these 13 patients, 9 went into molecular remission (MR) as demonstrated by the 
normalization of WT1 transcript levels in blood and/or bone marrow (UPN01, 06, 08, 10, 11, 
14, 15, 16, 17). Of these 9 patients, 2 went from PR to CR (UPN08, 16),17 and 5 are still in 
CR (UPN06, 08, 10, 14, 15) with a median duration of 114.5 months (mo) and a median 
follow-up after the first WT1/DC vaccination of 109.4 mo. Four patients relapsed after 
reaching MR, 3 ultimately dying of AML (UPN01, 11, 16) and 1 achieving long-term CR after 
undergoing allo-HSCT (UPN17). In all relapsing patients, recurrence of AML was preceded 
and accompanied by increased WT1 transcript levels. In the remaining 4 patients (UPN21, 
33, 35, 48), the clinical response was characterized by stable disease (SD) as demonstrated 
by elevated but stable WT1 transcript levels in blood and stable blood values without blasts. 
An example of SD is shown in Figure 2. The stable WT1 profile seen during SD contrasts 
with the steeply rising curve that is usually seen when AML patients are relapsing.19,23,25 
 Only a minority of patients had a molecular MRD marker other than WT1 mRNA. 
Overall, there was a corresponding evolution, between the WT1 transcript levels and other 
markers of MRD, such as the fusion transcripts RUNX1-RUNX1T1 (translocation t(8;21)) and 
CBFB-MYH11 (inversion inv(16)). For instance, in clinical responder UPN15, the 
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normalization of bone marrow WT1 expression after 4 WT1/DC vaccinations (from 638 to 4 
copies/1000 ABL copies) was paralleled by a decrease of RUNX1-RUNX1T1 transcript levels 
from 1.43 to 0.0495 copies/1000 ABL copies. In non-responder UPN28, the increase in 
already elevated blood WT1 transcript levels (from 24.1 to 1195 copies/1000 ABL copies) 
was mirrored by an increase of CBFB-MYH11 levels from 10 to 469 copies/1000 ABL copies. 
The clinical response rate was 50% in patients with favorable cytogenetic risk (MR in 
3/6 patients). Among the 22 treatment response-evaluable patients with intermediate 
cytogenetic risk, 6 patients experienced a MR and 4 other patients SD, corresponding to a 
clinical response rate of 45%. The response to WT1/DC vaccination, grouped according to 
the WT1 construct used, is indicated in Figure 1 and Table S1. Of the 29 patients with a 
definable response or non-response, there was an effect in 8/16 in the “WT1” group, 3/5 in 
the “WT1-DC-LAMP” group and 2/8 in the “WT1-DC-LAMP-OPT” group. Of the 3 patients 
receiving DCs prepared without KLH (UPN11, 12, 13), 1 achieved MR (UPN11). 
Overall, 6/30 patients (UPN06, 08, 10, 14, 15 and 22) have not relapsed yet and are 
still in CR1 with a median duration of 107.6 mo and a median follow-up of 101.8 mo after the 
first dose of WT1/DCs. Of the remaining 24/30 patients, 1 did not reach CR1 (UPN20), 1 died 
presumably of a lung adenocarcinoma without morphological evidence of AML relapse 
(UPN07), 3 had a second or third relapse (UPN02, 16, 34) and 19 a first relapse. Four of 
these 19 AML patients in first relapse received supportive care (UPN01, 11, 21, 38), whereas 
the remaining 15 patients were treated with salvage therapy (chemotherapy with or without 
allo-HSCT; Table S1). The CR2 rate in this group was 73.3% (11/15 patients: UPN05, 12, 
13, 17, 28, 30, 35, 36, 46, 47, 48); the remaining 4 patients had progressive disease 
(UPN03, 09, 29, 33). 
 
Survival 
Survival data are shown in Figures 1 and 3, and Tables 1 and S1. The 5-yr relative OS data 
compared favorably with those reported by the SEER program of the National Cancer 
Institute.1 OS and relapse-free survival (RFS) were significantly higher in responders as 
compared to non-responders, irrespective of age categories. The OS data were not 
influenced significantly by allo-HSCT, which was carried out in some patients who relapsed 
during WT1/DC vaccination (data not shown).   
Of the patients in first CR (CR1; Table 1) who received WT1/DCs, survival from 
diagnosis compared favorably with that of patients from the Swedish Acute Leukemia 
Registry (SALR), a comprehensive population-based AML database.31 The 5-yr relative RFS 
of AML patients in CR1 treated with WT1/DCs was similar to that of the SALR. It should be 
noted that the risk of relapse in the patients treated with WT1/DCs was most probably higher 
than that of SALR patients, part of whom (overall 32.1%) did not relapse after 5 yr (Table 1). 
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In contrast, 25/26 patients who were vaccinated with WT1/DCs were destined to relapse 
based on increased pre-vaccination WT1 transcript levels and/or relapsed. The RFS of 
responding patients was markedly better than the RFS of patients from the SALR. Of the 25 
response-evaluable patients in CR1, 5 have not relapsed yet (UPN06, 08, 10, 14, 15; all of 
them responders), compatible with a vaccine-induced relapse reduction rate of 25%. The 
median duration of CR1 in these 5 patients has been indicated above. There were 16/30 
patients in the long-term survivor category (UPN01, 06, 08, 10, 11, 12, 14, 15, 17, 21, 22, 28, 
29, 33, 34, 35).  
Long-term survival was observed in 11/13 responders and in 4/16 non-responders; 
the difference is significant (P=0.0025, Fisher’s exact test), correlating long-term survival with 
response to WT1/DCs. Long-term survival was noted in 5/6 and 10/22 response-evaluable 
patients with respectively favorable and intermediate cytogenetic risk; the difference between 
the 2 groups was not significant (P=0.20). There were no significant differences in OS 
outcome between the different WT1 constructs used (Figure 1; “WT1” vs. “WT1-DC-LAMP”, 
P=0.48; “WT1” vs. “WT1-DC-LAMP-OPT”, P=0.44; “WT1-DC-LAMP” vs. “WT1-DC-LAMP-
OPT”, P=0.84; “WT1” vs. “WT1-DC-LAMP” + “WT1-DC-LAMP-OPT”, P=0.34). 
As shown in Table S1, as of December 31, 2016, 11/30 patients were alive in CR with 
a median OS from diagnosis of 99.4 mo (range 72.6 – 125.5 mo). Of these 11 patients, 6 
were alive in continuing CR1 (UPN06, 08, 10, 14, 15, 22). Five other surviving patients who 
relapsed after WT1/DC vaccination were brought back into CR by chemotherapy followed 
(UPN17, 28) or not (UPN12, 34, 35) by allo-HSCT. Remarkably, patients UPN12 and 34 are 
alive in continuing CR respectively more than 7 yr and 4 yr, after achieving CR2 and CR3 
with chemotherapy alone. 
Of the 19 AML patients, who were in first relapse after WT1/DC vaccination, 52.6% 
were alive at 3 yr and 36.8% at 5 yr from diagnosis. Of the latter patients, 4 achieved CR2 
following chemotherapy (UPN12, 17, 28, 35), while the other 3 had a remarkably long period 
of CR1 before relapsing (UPN01, 11, 29: respectively 47, 51.6 and 59.8 mo after the start of 
WT1/DC vaccination). 
 
WT1/DC vaccine-induced immune responses 
Immunomonitoring was performed on PBMCs, DILs and plasma samples obtained before 
and/or after WT1/DC vaccination. There were no significant changes after vaccination with 
respect to: (i) the frequencies or absolute numbers of circulating lymphocyte subsets (CD4+ 
and CD8+ T-cells, B-cells and natural killer cells); (ii) the relative frequencies of naïve, 
terminally differentiated effector, effector memory, central memory subsets within the CD4+ 
and CD8+ T-cell compartments; (iii) the relative frequencies of regulatory T-cell subsets; or 
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(iv) the relative frequencies of myeloid-derived suppressor cells. T-helper (Th)1/Th2 cytokine 
levels and anti-WT1 IgG titers in plasma were also unchanged after WT1/DC vaccination.  
WT1-specific T-cell responses were evaluated using pHLA-A*0201 tetramer staining 
and intracellular cytokine assays. Increased (>1.5-fold) frequencies of WT1-specific tetramer+ 
CD8+ T-cells were observed after vaccination in 6/12 evaluable (HLA-A*0201+) patients. A 
significant positive correlation (P=0.018) was found between long-term clinical response 
(UPN01, 08, 35) and increased circulating frequencies of poly-epitope WT1-specific 
tetramer+ CD8+ T-cells (Table S2). Of the 9 HLA-A*0201+ non-responder patients, only 
UPN30 had increased numbers of poly-epitope WT1-specific CD8+ T-cells. The other non-
long-term responders showed either no (6/9 patients) or mono-epitope (2/9 patients) WT1-
specific CD8+ T-cell responses to WT1/DC vaccination. WT1-specific tetramer+ CD8+ T-cells 
were also assessed in 7 HLA-A*0201+ patients (UPN16, 17, 30, 34, 35, 38, 47) at relapse or 
disease progression: the frequencies were not lost in any patient upon relapse. In all but one 
patient (UPN16), we observed an increase of frequencies for at least 2 epitopes as 
compared to the post 4th WT1/DC vaccination sample and in all patients a maintenance 
and/or increase for the other epitope(s) examined (data not shown).  
Because KLH was shown in our previous study17 to skew the T-cells towards a Th2 
profile, which could be detrimental for a cytotoxic antitumoral response, it was omitted from 
the preparation of the DCs in 3 patients (UPN11, 12, 13). In those patients, there was no 
local immunoreactivity at the site of DC injection, nor was there any DTH reactivity and it was 
thus impossible to assess in vivo the quality of the DCs for their capacity to migrate to the 
lymph nodes and to elicit T-cell response. For this reason, it was therefore decided to 
reincorporate KLH in the DC vaccine preparation in all other patients. All the KLH-exposed 
patients showed a DTH response; in 13 of them, DILs were obtained for immune response 
assessment. Functional analysis of DILs restimulated with autologous WT1-loaded DCs 
demonstrated WT1-specific CD8+, but not CD4+ T-cell responses after vaccination, as shown 
by significant increases in WT1-specific interferon (IFN)-γ and tumor necrosis factor (TNF)-α, 
but not IL-5 production. This vaccine-specific CD8+ T-cell response was present in the long-
term, but not in the non-long-term survivor group (Figure 4A-B-C). Notably, significant WT1-
specific bifunctional TNF-α+/IFN-γ+ CD8+ T-cell responses were also detected in the long-
term survivor group (Figure 4D). In some long-term responders (UPN14) or survivors 
(UPN17, 34, 35), the proportion of IFN-γ+ and/or TNF-α+ WT1-specific CD8+ DILs was very 
high (range 5%-50%). IFN-γ+ and TNF-α+ WT1-specific CD8+, but not CD4+ DIL responses 
were significantly higher in patients vaccinated with the DC-LAMP-containing WT1 constructs 
as compared to those vaccinated with the wild type WT1 construct (data not shown).  
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DISCUSSION 
 
In this phase II study, we demonstrated clinical activity of autologous WT1 mRNA-
electroporated DC vaccination in patients with AML in remission and showed that this form of 
cancer vaccine therapy may offer overall survival (OS) benefit that is linked to the induction 
of WT1-specific CD8+ T-cell immunity. The clinical response rate that was obtained in this 
study (43%) is of considerable interest, with 30% of molecular response (MR) and 13% of 
stable disease (SD). The high rate of patients achieving MR (9/30 patients) is an important 
finding, since these patients were otherwise destined to relapse based on their increased 
pre-vaccination WT1 transcript levels.19,21-25 In the SD response group (4/30 patients), 
WT1/DC vaccination was effective in temporarily halting AML progression (as characterized 
by stabilization of WT1 transcript levels and stable blood values without blasts), thereby 
delaying the occurrence of florid relapse. SD is an unexpected response category in the 
context of AML, where relapses are normally characterized by exponentially increasing WT1 
transcript levels at a constant doubling time.19 Similar observations of disease stabilization 
have been made in WT1 peptide vaccine trials in AML,7,8,32 indicating that SD should be 
included as a separate category in the response assessment of immunotherapeutic 
interventions in hematological malignancies as it is now routinely the case in the field of solid 
tumor immunotherapy.33 Altogether, the data above indicate that WT1-targeted DC 
vaccination can be an effective strategy to prevent or delay relapse in AML, without the 
toxicity of allo-HSCT. This is an important finding in light of the growing number of elderly 
AML patients who are generally not considered candidates for allo-HSCT because of toxicity 
considerations.5 Based on these results, a place for WT1/DC vaccination can also be 
foreseen for younger AML patients who do not proceed to allo-HSCT after standard 
chemotherapy because of refusal or lack of a suitable donor.  
The OS data in this study compared favorably with current and new data from SEER 
and SALR, respectively. Importantly, this comparatively longer OS was observed not only in 
younger patients (≤65 yr) but also in the bad prognosis older age category (>65 yr). Long-
term OS were seen in both favorable and intermediate cytogenetic risk groups. OS and RFS 
also correlated with the clinical response to WT1/DCs. These observations further validate 
the use of WT1 transcript levels as a suitable marker for leukemic residual disease and for 
monitoring the effect of therapy in AML. Increased OS in AML was recently found to correlate 
with reduced WT1 mRNA levels and WT1-specific CD8+ T-cell responses in a cohort of AML 
patients after chemotherapy and allo-HSCT.34 The comparatively longer OS observed in AML 
patients vaccinated with WT1/DCs is consistent with a meta-analysis indicating that DC 
vaccine therapy can offer OS benefit in patients with solid malignancies, including 
melanoma, prostate cancer, glioblastoma multiforme and renal cell cancer.14 
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Intriguingly, 5-yr relative OS but not relapse-free survival (RFS) of the patients 
vaccinated with WT1/DCs compared favorably with the SALR data. Our data suggest that 
one  major reason for the OS advantage is the unexpectedly high clinical response rate and 
long survival in the patients who had relapsed after WT1/DC vaccination. For AML patients in 
first relapse, the probability of achieving a second CR with salvage treatment (i.e. 
chemotherapy and/or allo-HSCT) has been reported to be 46%,35 whereas the CR2 rate in 
our study was 73.3%. Likewise, the 5-yr OS rate of WT1/DC-vaccinated AML patients 
following first relapse was 36.8% in this study, which compares favorably to the 11% 5-yr OS 
rate of AML patients in first relapse that has been described in the literature.35 These data 
suggest that WT1/DC vaccination can potentiate the response to subsequent treatment, 
providing an explanation for how vaccination contributes to prolongation of survival. A similar 
scenario has been reported for solid tumors, where improved clinical outcomes have been 
documented in patients who received chemotherapy after apparently failing immunotherapy 
as compared to patients who received chemotherapy alone.36-44 This outcome may reflect 
synergism between immunotherapy and chemotherapy, the latter having not only anti-
proliferative but also immunostimulatory effects.6,13 The precise mechanisms underlying the 
anticancer synergy between tumor vaccines and chemotherapy are currently being 
investigated;41 one potential mechanism involves the release of cytokines (such as TNF-α) 
by vaccine-induced CD8+ T-cells, which in turn enhances the ability of chemotherapy to 
induce apoptotic tumor cell death.45 
 In this study, clinical response and survival were found to be correlated with induction 
of WT1-reactive CD8+ T-cell immunity by the DC vaccination, providing a mechanistic basis  
for the anti-leukemic activity of WT1/DCs. First, we found a correlation between long-term 
clinical response and increased circulating frequencies of poly-epitope WT1-specific 
tetramer+ CD8+ T-cells. The maintenance or increase of the frequencies of WT1-specific 
CD8+ T-cells at relapse or progression, points towards antigen-driven immune activation 
associated with increasing exposure to the WT1 antigen at relapse46 and with the 
continuation of the WT1/DC vaccination. This suggests that antigen-specific T-cell numbers 
may be necessary, but not sufficient to ultimately control AML. Second, we found a 
correlation between WT1-specific IFN-γ+ and/or TNF-α+ DTH-infiltrating CD8+ T-lymphocytes 
and long-term OS. This suggests that CD8+ T-cell function is needed for long-term control of 
AML, at least in the immunotherapy setting. Since DTH was not performed in this study at 
the time of relapse, we cannot exclude that despite a maintenance or increase in WT1-
specific cell numbers, their function may be deficient at that time. 
In line with preclinical data,18 3 different WT1 constructs were used in this study: a 
native full-length WT1 construct, a WT1 construct incorporating the lysosomal targeting 
signal of DC-LAMP, and a codon-optimized version of the latter construct. Theoretically, the 
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DC-LAMP-containing constructs would facilitate MHC class II antigen presentation and 
subsequent CD4+ T-cell stimulation. Contrary to expectations, no statistical evidence for 
induction of WT1-specific CD4+ T-cell immunity was found in the patients in whom the DC-
LAMP-containing constructs were used. This is in contrast with a recently published study in 
melanoma, which used DCs loaded with melanoma antigen-encoding mRNA linked to a 
similar DC-LAMP construct.47 The apparent lack of CD4+ T-cell stimulation in our hands may 
be due to the fact that the strongly immunogenic WT1332-347 MHC class II epitope48,49 is not 
encoded by the DC-LAMP-containing constructs because they lack the WT1 nuclear 
localization signal (NLS).18 Nevertheless, even without a significantly increased stimulation of 
WT1-specific CD4+ T-cells, the DC-LAMP-containing constructs did induce higher 
frequencies of WT1-specific CD8+ T-cells as compared to the wild-type WT1 construct, 
presumably as a consequence of higher cytoplasmic WT1 expression and MHC class I 
epitope presentation.18  This, however, did not translate in superior clinical response rates, 
nor in improved survival outcome. 
In summary, WT1-targeted DC vaccination can elicit anti-leukemia T-cell immunity in 
AML patients at very high risk of relapse. The induction of functional WT1-specific CD8+ T-
cells is a likely mechanism to help eliminate residual leukemic cells, decrease the likelihood 
of AML relapse and improve survival. Vaccination with WT1/DCs can therefore be 
considered as a non-toxic, post-remission strategy to prevent or delay relapse of AML in the 
adjuvant setting. 
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TABLE 1 
 
 
  This study
◊
 
SALR
†
 
 
 
  All Responders
 
 Non-responders  
 
 
All ages  n=26 n=12 n=13 n=2495 
 
 
OS median 56.1 mo n.r. [101.7 mo] 21.1 mo 29.9 mo 
 
 
 5-yr % 50.0 % 75.0 % 23.1 % 37.9 % 
 
 
RFS median 14.2 mo 59.6 mo 8.7 mo 16.7 mo 
 
 
 5-yr % 30.8 % 50.0 % 7.7 % 32.1 % 
 
 
≤65 years  n=13 n=6 n=6 n=1542 
 
 
OS median n.r. [101.7 mo] n.r. [115.9 mo] 29.1 mo 74.8 mo 
 
 
 5-yr % 69.2 % 100 % 33.3 % 51.7 % 
 
 
RFS median 58.0 mo n.r. [114.8 mo] 9.4 mo 30.3 mo 
 
 
 5-yr % 46.2 % 66.7 % 16.7 % 43.9 % 
 
 
>65 years  n=13 n=6 n=7 n=953 
 
 
OS median 32.2 mo 59.2 mo 21.1 mo 18.2 mo 
 
 
 5-yr % 30.8 % 50.0 % 14.3 % 18.0 % 
 
 
RFS median 11.5 mo 41.0 mo 6.4 mo 10.6 mo 
 
 
 5-yr % 15.4 % 33.3 % 0.0 % 14.9 % 
 
 
◊
, all newly diagnosed acute myeloid leukemia (AML) patients in first complete remission (CR1) enrolled in the dendritic cell (DC) 
vaccination studies NCT00834002 and NCT00965224; three AML patients who were in second or third CR (UPN02, UPN16 and 
UPN34) and one AML patient who did not reach CR1 (UPN20) were excluded from analysis. 
 
, all study patients who responded to DC 
vaccination; patient UPN22 had an undefinable response and was excluded from analysis. 
†
, observed survival of newly diagnosed 
AML patients in CR1 enrolled in the Swedish Acute Leukemia Registry (SALR), diagnosis from 1997-2014. OS, overall survival 
calculated from time of diagnosis. RFS, relapse-free survival calculated from start of CR1. Median, median survival expressed in 
months (mo). 5-yr %, 5-year survival percentage (%). n.r., median survival not reached. [ number ], median follow-up time in months 
(mo). { P= }’, p value (Gehan-Breslow-Wilcoxon test) of the survival comparison between “Responders” and “Non-responders”.  
 
 
 
Table 1. Overall survival (OS) and relapse-free survival (RFS) of AML patients in first complete 
remission (CR1) enrolled in this study as compared to the Swedish Acute Leukemia Registry 
(SALR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
P=0.0043 
P=0.0179 
P=0.0270 
P=0.0019 
P<0.0001 
P=0.0059 
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FIGURES AND FIGURE LEGENDS 
 
Figure 1. The three different WT1 constructs used to generate mRNA for 
electroporation into DCs and their corresponding clinical responses and survival 
outcome. Construct 1 (“WT1”) encodes full-length WT1 (A), construct 2 (“WT1-DC-LAMP”) 
includes a Sig-DC-LAMP major histocompatibility complex (MHC) class II-skewing signal with 
deletion of the WT1 nuclear localization signal (B) and construct 3 (“WT1-DC-LAMP-OPT”) is 
a codon-optimized version of construct 2 (C). For further details, see reference18 MR, 
molecular remission; SD, stable disease; Undef., undefinable; median OS, median overall 
survival calculated from the start of WT1/DC vaccination; the values between square 
brackets represent median follow-up; mo, months; 5-yr % OS, 5-year overall survival 
percentage from the start of WT1/DC vaccination; UTR, untranslated region; NLS, nuclear 
localization signal. The full color blue bars represent the remaining coding sequence of WT1 
in constructs 2 and 3. The SD phase in UPN35 started during the administration of DCs 
electroporated with construct 3 (see Table S1). 
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Figure 2. Stable disease (SD) in patient UPN33 during (arrows) and after WT1/DC 
vaccination. WT1 transcript levels (determined by the Ipsogen WT1 ProfileQuant Kit) in 
blood (A) and bone marrow (B) were above background (indicated by the dotted blue line) 
but remained stable, and the bone marrow blast count normalized (normal value indicated by 
the dotted pink line). Blood values (C) showed pancytopenia at the start of DC vaccination, 
but a normal hemoglobin level (without transfusions) at the end of the SD period (at 19 
months); neutropenia was treated with granulocyte colony-stimulating factor (G-CSF). CTx 
(I+C), polychemotherapy (induction + 2 consolidations); 4 x biw + DTH, period of the first 4 
biweekly WT1/DC vaccinations and DTH;  ANC, absolute neutrophil count. 
 
 
ANGUILLE et al    DENDRITIC CELLS AS POST-REMISSION TREATMENT IN AML 
 
24 
Figure 3. Kaplan-Meier curves of the overall survival data. The values on the curves are 
5-yr relative survival from the start of WT1/DC vaccination; the values underneath in gray (A, 
B, C) are 5-yr relative survival data from SEER (observed survival of newly diagnosed AML 
patients included in Surveillance, Epidemiology and End Results (SEER)*Stat Database 
“Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, 
Nov 2014 Sub (1973-2012 varying)”, whereby the following case selection criteria were 
applied: age (min. age 30 years, max. age 79 years), race (white) and year of diagnosis 
(2005-2012); the patient with an undefinable response (UPN22) was not included in figure 
3D. mOS, median overall survival; the values between square brackets represent median 
follow-up; mo, months; n.r., not reached.  
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Figure 4. Intracellular cytokine 
staining of CD8+ DILs after 
restimulation with mature DCs 
alone (‘mDC’) or WT1 mRNA-
electroporated DCs (‘mDC 
WT1’). The WT1-specific T-cell 
cytokine response was evaluated 
by comparing ‘mDC WT1’ with 
‘mDC’ (all patients examined: 
UPN03, 05, 06, 08, 14, 17, 21, 22, 
29, 30, 34, 35, 47; long-term 
survivors: UPN06, 08, 14, 17, 21, 
22, 29, 34, 35; non-long-term 
survivors: UPN03, 05, 30, 47). 
IFN-γ+, IL-5+ or TNF-α+ CD8+ T-
cells are shown for all patients 
(A), long-term survivors (B) and 
non-long-term-survivors (C). 
Polyfunctional TNF-α+/IFN-γ+ 
CD8+ T-cells are shown in the 
same patients (D). *, statistically 
significant difference; LT, long-
term. 
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